drugset / Trial / NCT01398241
A Study of RO5267683 in Healthy Subjects
RandomizedParallel-groupDouble-blind
Summary
This investigator-blind, subject-blind, randomized, placebo-controlled study will evaluate the safety, pharmacokinetics and pharmacodynamics of multiple ascending doses of RO5267683 in healthy volunteers. Subjects will be randomized to receive either RO5267683 or placebo orally daily for 28 days. Follow-up will be 10 weeks after the last dose.
Timeline
- Start
- 2011-08
- Primary completion
- 2012-06
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RO5267683 | Unknown | — | Oral |
Indications
No indication recorded.